Revolutionary diagnostic HART blood tests and platform by Prevencio
AI-driven HART blood tests demonstrate high accuracy in diverse patient populations and beyond cardiac disease
31 Jul 2023Prevencio announced the culminative presentation of patient data demonstrating that its artificial intelligence (AI)-driven HART® blood tests are highly accurate in a broad range of patients, including those with diabetes, chronic kidney disease, hypertension, obesity, coronary heart disease, heart failure, chronic total occlusion (CTO) of the heart arteries, and Kawasaki disease. The HART platform is disease agnostic and may be used to develop diagnostics beyond cardiac disease.
Prevencio’s two lead tests, HART CVE™ and HART CADhs™ , are currently available to medical professionals for patient use. HART CVE determines a patient’s one year risk for a heart attack, stroke, or cardiovascular death, while HART CADhs assesses whether a patient has obstruction of the heart arteries and is at imminent risk of a heart attack.
Researchers from Massachusetts General Hospital (MGH) tested more than 1,250 patients undergoing coronary or peripheral angiography to collaborate in the development and validation of the AI-driven HART platform which has produced seven highly accurate, algorithmic multiple protein blood tests.
“It is impressive the HART tests provide robust accuracy amongst a wide range of patients,” said James L. Januzzi, MD, a practicing cardiologist at MGH, Professor of Medicine at Harvard Medical School, Director of Biomarker Trials at the Baim Institute for Clinical Research, and Principal Investigator in development, validation, and ongoing testing of six of the seven HART tests. “With the rapid rise in cardiovascular disease, better tools to recognize risk and intervene proactively are needed. Our data suggest that AI-derived, multi-protein, algorithmically scored blood tests may be useful to individualize cardiac risk assessment and foster aggressive primary and secondary cardiovascular prevention. We are especially excited with our most recent data demonstrating the accuracy of HART CVE in assessing risk in patients with total chronic occlusion of the coronary arteries and look forward to using the HART platform to develop additional clinical applications and diagnostic tests.”